Argenica Therapeutics Ltd (AU:AGN) has released an update.
Argenica Therapeutics Limited is progressing well with their Phase 2 clinical trial for acute ischaemic stroke, having activated eight out of ten hospitals and successfully dosed 20 patients since the trial’s inception in March 2024. The recruitment is on schedule, and the company aims to dose all 92 patients by the end of 2025, with the Data Safety Monitoring Board providing oversight to ensure patient safety throughout the study.
For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.
